Product Name :
DR2313
Description:
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo.
CAS:
284028-90-6
Molecular Weight:
182.24
Formula:
C8H10N2OS
Chemical Name:
2-methyl-1H,4H,5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-one
Smiles :
CC1NC2CCSCC=2C(=O)N=1
InChiKey:
HRYKZAKEAVZGJD-UHFFFAOYSA-N
InChi :
InChI=1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo.|Product information|CAS Number: 284028-90-6|Molecular Weight: 182.24|Formula: C8H10N2OS|Chemical Name: 2-methyl-1H,4H,5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-one|Smiles: CC1NC2CCSCC=2C(=O)N=1|InChiKey: HRYKZAKEAVZGJD-UHFFFAOYSA-N|InChi: InChI=1S/C8H10N2OS/c1-5-9-7-2-3-12-4-6(7)8(11)10-5/h2-4H2,1H3,(H,9,10,11)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 12.5 mg/mL (68.59 mM; Need ultrasonic). H2O : ≥ 100 mg/mL (548.73 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.Clarithromycin In stock |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.Naxitamab Data Sheet |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|DR2313 (0.PMID:32583397 016-16.4 μM; 30 min) inhibits poly(ADP-ribosyl)ation reaction in nuclear extracts of rat brain, with a Ki of 0.23 μM. DR2313 shows more powerful inhibition of the poly(ADP-ribosyl)ation in the nuclear extracts of the rat brain (IC50=0.20 μM) than 3AB (35.4 μM), PND (0.56 μM), DIQ (2.96 μM), and DPQ (0.96 μM). DR2313 (1-100 μM; 10 min) shows a weak inhibition of the mono(ADP-ribosyl)ation in a concentration-dependent manner (IC50=59 μM). DR2313 (0.1-30 μM; pretreated for 30 min) reduces hydrogen peroxide (500 μM; 4 h) or glutamate (1 mM; 30 min) induced excessive formation of poly(ADP-ribose) and cell death.|In Vivo:|DR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats.|Products are for research use only. Not for human use.|
